Latest Insider Transactions at Exelixis, Inc. (EXEL)
This section provides a real-time view of insider transactions for Exelixis, Inc. (EXEL). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of EXELIXIS, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of EXELIXIS, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 26
2022
|
Carl B Feldbaum Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,180
+35.25%
|
-
|
|
May 26
2022
|
Maria C Freire Director |
BUY
Grant, award, or other acquisition
|
Direct |
19,575
+24.69%
|
-
|
|
May 26
2022
|
Jack L Wyszomierski Director |
BUY
Grant, award, or other acquisition
|
Direct |
19,575
+6.27%
|
-
|
|
May 26
2022
|
Jacqueline Wright Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,180
+24.7%
|
-
|
|
May 26
2022
|
Vincent T Marchesi Director |
BUY
Grant, award, or other acquisition
|
Direct |
19,575
+17.24%
|
-
|
|
May 26
2022
|
Stelios Papadopoulos Director |
BUY
Grant, award, or other acquisition
|
Direct |
19,575
+1.55%
|
-
|
|
May 26
2022
|
George Poste Director |
BUY
Grant, award, or other acquisition
|
Direct |
19,575
+9.2%
|
-
|
|
May 16
2022
|
Jeffrey Hessekiel EVP & General Counsel |
SELL
Open market or private sale
|
Direct |
18,000
-2.98%
|
$360,000
$20.07 P/Share
|
|
May 15
2022
|
Jeffrey Hessekiel EVP & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
5,349
-0.88%
|
$106,980
$20.08 P/Share
|
|
May 15
2022
|
Peter Lamb EVP, Scientific Strategy & CSO |
SELL
Payment of exercise price or tax liability
|
Direct |
6,123
-1.52%
|
$122,460
$20.08 P/Share
|
|
May 15
2022
|
Christopher J. Senner EVP and CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
8,444
-1.96%
|
$168,880
$20.08 P/Share
|
|
May 15
2022
|
Patrick J. Haley EVP, Commercial |
SELL
Payment of exercise price or tax liability
|
Direct |
11,723
-2.19%
|
$234,460
$20.08 P/Share
|
|
May 12
2022
|
Lance Willsey Director |
SELL
Open market or private sale
|
Direct |
40,000
-8.61%
|
$760,000
$19.65 P/Share
|
|
May 12
2022
|
Lance Willsey Director |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+7.93%
|
$120,000
$3.13 P/Share
|
|
Apr 04
2022
|
Jack L Wyszomierski Director |
SELL
Open market or private sale
|
Direct |
6,696
-2.39%
|
$154,008
$23.0 P/Share
|
|
Apr 04
2022
|
Jack L Wyszomierski Director |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+12.5%
|
$120,000
$3.13 P/Share
|
|
Apr 01
2022
|
Patrick J. Haley EVP, Commercial |
SELL
Open market or private sale
|
Direct |
10,000
-3.58%
|
$230,000
$23.0 P/Share
|
|
Apr 01
2022
|
Patrick J. Haley EVP, Commercial |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+3.46%
|
$60,000
$6.21 P/Share
|
|
Mar 31
2022
|
Patrick J. Haley EVP, Commercial |
SELL
Open market or private sale
|
Direct |
10,000
-3.58%
|
$220,000
$22.43 P/Share
|
|
Mar 31
2022
|
Patrick J. Haley EVP, Commercial |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+3.46%
|
$60,000
$6.21 P/Share
|
|
Mar 29
2022
|
Jeffrey Hessekiel EVP & General Counsel |
SELL
Open market or private sale
|
Direct |
13,283
-2.15%
|
$292,226
$22.0 P/Share
|
|
Mar 28
2022
|
Jeffrey Hessekiel EVP & General Counsel |
SELL
Open market or private sale
|
Direct |
4,717
-0.76%
|
$103,774
$22.0 P/Share
|
|
Mar 04
2022
|
Peter Lamb EVP, Scientific Strategy & CSO |
BUY
Grant, award, or other acquisition
|
Direct |
59,490
+12.88%
|
-
|
|
Mar 04
2022
|
Patrick J. Haley EVP, Commercial |
BUY
Grant, award, or other acquisition
|
Direct |
70,715
+20.8%
|
-
|
|
Mar 04
2022
|
Jeffrey Hessekiel EVP & General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
67,875
+9.82%
|
-
|
|
Mar 04
2022
|
Christopher J. Senner EVP and CFO |
BUY
Grant, award, or other acquisition
|
Direct |
75,985
+15.02%
|
-
|
|
Mar 04
2022
|
Michael Morrissey President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
270,415
+40.38%
|
-
|
|
Mar 02
2022
|
Michael Morrissey President and CEO |
SELL
Bona fide gift
|
Indirect |
50,000
-4.01%
|
-
|
|
Mar 01
2022
|
Alan M Garber Director |
SELL
Open market or private sale
|
Direct |
21,301
-40.41%
|
$447,321
$21.0 P/Share
|
|
Mar 01
2022
|
Alan M Garber Director |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+43.14%
|
$120,000
$3.13 P/Share
|
|
Feb 25
2022
|
Patrick J. Haley EVP, Commercial |
SELL
Open market or private sale
|
Direct |
31,238
-13.6%
|
$593,522
$19.53 P/Share
|
|
Feb 24
2022
|
Jeffrey Hessekiel EVP & General Counsel |
SELL
Open market or private sale
|
Direct |
18,000
-3.14%
|
$360,000
$20.0 P/Share
|
|
Feb 22
2022
|
Carl B Feldbaum Director |
SELL
Open market or private sale
|
Direct |
20,000
-70.12%
|
$380,000
$19.49 P/Share
|
|
Feb 22
2022
|
Carl B Feldbaum Director |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+41.22%
|
$60,000
$3.13 P/Share
|
|
Feb 22
2022
|
Stelios Papadopoulos Director |
SELL
Open market or private sale
|
Direct |
84,515
-6.48%
|
$1,605,785
$19.56 P/Share
|
|
Feb 15
2022
|
Patrick J. Haley EVP, Commercial |
SELL
Payment of exercise price or tax liability
|
Direct |
15,527
-3.18%
|
$279,486
$18.59 P/Share
|
|
Feb 15
2022
|
Christopher J. Senner EVP and CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
18,327
-2.48%
|
$329,886
$18.59 P/Share
|
|
Feb 15
2022
|
Michael Morrissey President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
65,147
-17.28%
|
$1,172,646
$18.59 P/Share
|
|
Feb 15
2022
|
Jeffrey Hessekiel EVP & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
12,226
-1.05%
|
$220,068
$18.59 P/Share
|
|
Feb 15
2022
|
Peter Lamb EVP, Scientific Strategy & CSO |
SELL
Payment of exercise price or tax liability
|
Direct |
20,177
-2.79%
|
$363,186
$18.59 P/Share
|
|
Feb 03
2022
|
Patrick J. Haley EVP, Commercial |
SELL
Open market or private sale
|
Direct |
60,000
-19.66%
|
$1,020,000
$17.91 P/Share
|
|
Feb 03
2022
|
Patrick J. Haley EVP, Commercial |
BUY
Exercise of conversion of derivative security
|
Direct |
60,000
+16.43%
|
$60,000
$1.9 P/Share
|
|
Jan 04
2022
|
Vicki L Goodman EVP, Prod Dev & Med Aff &CMO |
SELL
Payment of exercise price or tax liability
|
Direct |
7,613
-3.05%
|
$144,647
$19.18 P/Share
|
|
Jan 04
2022
|
Vicki L Goodman EVP, Prod Dev & Med Aff &CMO |
BUY
Grant, award, or other acquisition
|
Direct |
250,000
+50.0%
|
-
|
|
Dec 16
2021
|
Jacqueline Wright Director |
BUY
Grant, award, or other acquisition
|
Direct |
20,858
+50.0%
|
-
|
|
Dec 15
2021
|
Jeffrey Hessekiel EVP & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
2,621
-0.45%
|
$44,557
$17.0 P/Share
|
|
Dec 15
2021
|
Jeffrey Hessekiel EVP & General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
9,994
+1.67%
|
-
|
|
Dec 15
2021
|
Christopher J. Senner EVP and CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
5,131
-1.36%
|
$87,227
$17.0 P/Share
|
|
Dec 15
2021
|
Christopher J. Senner EVP and CFO |
BUY
Grant, award, or other acquisition
|
Direct |
19,491
+4.91%
|
-
|
|
Dec 15
2021
|
Peter Lamb EVP, Scientific Strategy & CSO |
SELL
Open market or private sale
|
Direct |
47,500
-11.57%
|
$807,500
$17.44 P/Share
|